Vaxxas Appoints David Hoey as Company’s First CEO

You may also like

03 August 2020

KiRA Biotech appoints Global Pharma Business Leader as Independent Board Chair

21 October 2014

Hatchtech announces successful results from Phase 2 ovicidal study

31 October 2013

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

13 August 2018

OneVentures invests in regional Queensland company developing treatments for autoimmune diseases

18 July 2016

DoseMe partners with Charm Health to improve management of high risk oncology medicines and deliver “precision medicine” to Australian cancer patients

26 August 2014

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Awards, Media Release

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor